Skip to content
Menu

Indaptus Therapeutics, Inc. INDP

Full chart Compare
Set alert

Price alert · INDP

All alert types
3.13 USD -0.16 (-4.86%)

Regular-session close

3.13 0.00 0.00%

After hours · Nov 19, 4:00 PM ET

3.10 Day range 3.31
0.92 52-week range 5.96
YTD
+7.56%
1 year
+51.21%

5D +0.02 (+0.64%)

3.203.403.60FriMonTueWedThu3.13
Market cap
480.78M
EPS (ttm)
-3.16
Shares out
12.01M
Forward P/E
-0.64
YTD return
+7.56%
1-year return
+51.21%
50-day average
1.16
200-day average
1.81
Volume
101.99K
Avg volume
908.86K
Open
3.25
Previous close
3.29
Day's range
3.10 – 3.31
52-week range
0.92 – 5.96
Beta
1.13
Price target
8.50 (+171.6%)

Key statistics

Enterprise value
4.81M
Price / book
0.62
Free cash flow
-7.41M
Total cash
7.30M
Total debt
130.80K
Return on equity
-127.04%
Short % of float
1.83%

Fundamental scorecard

6 of 25 checks passed on INDP’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
INDP Revenue — quarterly 0
INDP Net income — quarterly -1.05M
INDP EPS — quarterly -0.01

Earnings

INDP recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 12, 2024Sep 1, 2024-0.47-0.32+0.15+31.91%
Aug 12, 2024Jun 1, 2024-0.54-0.47+0.07+12.96%
May 8, 2024Mar 1, 2024-0.57-0.45+0.12+21.05%
Mar 13, 2024Dec 1, 2023-0.54-0.47+0.07+12.96%
Nov 6, 2023Sep 1, 2023-0.55-0.47+0.08+14.55%
Aug 14, 2023Jun 1, 2023-0.58-0.39+0.19+32.76%

Upgrades / downgrades

INDP analyst upgrades and downgrades
DateFirmActionFromTo
Nov 13, 2024Maxim GroupmainBuyBuy
Oct 16, 2024HC Wainwright & Co.reitBuyBuy
Jun 17, 2024HC Wainwright & Co.reitBuyBuy
Apr 15, 2024HC Wainwright & Co.reitBuyBuy
Sep 20, 2023HC Wainwright & Co.reitBuyBuy
Aug 15, 2023HC Wainwright & Co.reitBuyBuy

About Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on INDP — it syncs with the Stock Master app.

Insider holders

INDP insider holders
InsiderRelationLatest transactionDateShares held
ANDERSON GLEN RBeneficial Owner of more than 10% of a Class of SecurityPurchaseAug 13, 20230
MECKLER JEFFREY AChief Executive OfficerStock Award(Grant)Nov 24, 2024202,859

Institution ownership

INDP institution ownership
Holder% heldSharesValueReported
Vanguard Group Inc2.51%256,265227.84KSep 29, 2024
Investment House, LLC0.98%99,97688.89KSep 29, 2024
Geode Capital Management, LLC0.72%73,12965.02KSep 29, 2024
Strategy Asset Managers Llc0.44%45,33640.31KSep 29, 2024
Pine Valley Investments Ltd Liability Co.0.43%43,98339.10KSep 29, 2024
Renaissance Technologies, LLC0.27%27,10024.09KSep 29, 2024

Fund ownership

INDP fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.25%229,197203.78KSep 29, 2024
Fidelity Extended Market Index Fund0.43%44,16939.27KOct 30, 2024
Vanguard Extended Market Index Fund0.27%27,06824.07KSep 29, 2024
Fidelity NASDAQ Composite Index Fund0.14%14,12312.56KOct 30, 2024
Fidelity Total Market Index Fund0.13%12,94811.51KOct 30, 2024
Fidelity Series Total Market Index Fund0.09%9,3148.28KOct 30, 2024